Disease‐modifying therapies in Alzheimer's disease
Tóm tắt
Alzheimer's disease (AD) is a chronic, progressive, neurodegenerative disorder that places a substantial burden on patients, their families, and society. The disease affects approximately 5 million individuals in the United States, with an annual cost of care greater than $100 billion. During the past dozen years, several agents have been approved that enhance cognition and global function of AD patients, and recent advances in understanding AD pathogenesis has led to the development of numerous compounds that might modify the disease process. A wide array of antiamyloid and neuroprotective therapeutic approaches are under investigation on the basis of the hypothesis that amyloid beta (Aβ) protein plays a pivotal role in disease onset and progression and that secondary consequences of Aβ generation and deposition, including tau hyperphosphorylation and neurofibrillary tangle formation, oxidation, inflammation, and excitotoxicity, contribute to the disease process. Interventions in these processes with agents that reduce amyloid production, limit aggregation, or increase removal might block the cascade of events comprising AD pathogenesis. Reducing tau hyperphosphorylation, limiting oxidation and excitotoxicity, and controlling inflammation might be beneficial disease‐modifying strategies. Potentially neuroprotective and restorative treatments such as neurotrophins, neurotrophic factor enhancers, and stem cell–related approaches are also under investigation.
Tài liệu tham khảo
10.1001/archneur.60.8.1119
10.2105/AJPH.84.8.1261
10.1126/science.1072994
10.1212/01.WNL.0000142963.90204.58
10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
10.1016/S1566-2772(00)00016-5
10.1038/nature04533
10.1056/NEJMra040223
10.1021/bi026173d
10.1016/j.jalz.2006.07.001
10.1093/brain/85.3.411
10.1002/sim.1718
10.1016/S1474-4422(06)70677-9
Sampaio C, 2006, Alzheimer disease: disease modifying trials; where are we? where do we need to go? a reflective paper, J Nutr Health Aging, 10, 113
10.1038/22124
10.1385/JMN:24:1:105
10.1212/01.WNL.0000073623.84147.A8
10.1016/S0896-6273(03)00294-0
10.1212/01.WNL.0000159740.16984.3C
10.1212/01.WNL.0000159743.08996.99
10.1038/nm840
10.1111/j.1750-3639.2004.tb00493.x
Albert ML, 1975, Associative visual agnosia without alexia, Neurology, 25, 322, 10.1212/WNL.25.4.322
10.1136/jnnp.2003.033399
10.1038/85059
10.1093/hmg/10.12.1317
10.1111/j.1471-4159.2005.03576.x
10.1602/neurorx.2.4.612
10.1124/jpet.102.048280
10.2174/138161206775474233
May PC, 2004, Multi-compartmental pharmacodynamic assessment of the functional gamma-secretase inhibitor LY450139 dihydrate in PDAPP transgenic mice and non-transgenic mice, Neurobiol Aging, 25, S65
10.1124/jpet.104.075408
10.1523/JNEUROSCI.2693-05.2005
10.1212/01.WNL.0000198762.41312.E1
10.1096/fj.02-0394fje
10.1126/science.1065718
10.1074/jbc.M311652200
10.1212/WNL.47.2.425
10.1001/jama.289.21.2819
10.1046/j.1471-4159.2002.01195.x
10.1177/002383099200500108
JEMintzer GKWilcock SEBlack KHZavitz SBHendrix.MPC-7869 a selective Abeta42-lowering agent delays time to clinically significant psychiatric adverse events in Alzheimer's disease. analysis from a 12-month phase 2 trial. Presented as a poster exhibit at the 10th International Conference on Alzheimer's Disease and Related Disorders Madrid Spain.2006
10.1016/j.neurobiolaging.2006.02.015
PAisen SGauthier BVellas RBriand DSaumier JLaurin et al.Tramiprosate (Alzhemed™): A potential treatment for Alzheimer's disease. 9thInternational Geneva/Springfield Symposium on Advances in Alzheimer Therapy Geneva Switzerland.2006
10.1212/01.wnl.0000244346.08950.64
10.1002/ana.21051
10.1073/pnas.0604011103
10.1001/archneur.57.10.1439
10.1001/archneur.59.2.223
10.1073/pnas.081620098
10.1002/ana.10292
10.1001/archneur.62.5.753
10.1016/S0140-6736(02)11600-X
10.1001/archpsyc.62.2.217
Craft S, 2005, Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation, Neurobiol Aging, 26, 65, 10.1016/j.neurobiolaging.2005.08.021
10.1016/j.nbd.2004.08.003
10.1016/j.expneurol.2006.01.018
10.1097/00019442-200511000-00005
10.1038/sj.tpj.6500369
Geldmacher DS, 2006, Realistic expectations for treatment success in Alzheimer's disease, J Nutr Health Aging, 10, 417
10.1097/01.wad.0000213866.86934.7e
10.1007/0-387-23226-5_12
10.1016/S0896-6273(01)00317-8
10.1001/archneur.60.12.1685
10.1016/j.exger.2004.08.016
10.1016/j.neurobiolaging.2004.01.005
10.1111/j.1471-4159.2006.03770.x
10.1385/JMN:20:3:349
10.1007/s12031-002-0025-3
10.1016/j.neuron.2006.01.020
10.3109/13506120308995249
10.1001/archneur.1997.00550160091022
10.1038/nm890
10.1523/JNEUROSCI.23-01-00029.2003
10.1523/JNEUROSCI.3291-05.2006
10.1523/JNEUROSCI.4504-06.2006
10.1096/fj.03-0961fje
10.1345/aph.1G280
10.1159/000085074
10.1001/archneur.61.1.82
10.1001/archpsyc.1997.01830150083012
10.1056/NEJMoa050151
10.1080/10401230500296428
Cole GM, 2003, A rational for curcuminoids for the prevention or treatment of Alzheimer's disease, Curr Med Chem, 3, 15
10.2174/1567205053585882
10.2174/1568007053544084
10.1016/j.brainres.2004.09.046
10.1056/NEJM199104253241701
10.1001/archneur.55.11.1449
10.1002/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.0.CO;2-8
10.1056/NEJMoa011613
10.1523/JNEUROSCI.22-05-01752.2002
10.1182/blood-2005-06-2506
Finch CE, 2001, Molecular mechanisms of neurodegenerative diseases, 87
10.1212/WNL.54.3.588
10.1212/WNL.53.1.197
10.1212/WNL.62.1.66
10.1212/WNL.58.7.1050
10.1038/sj.npp.1300690
10.1046/j.1460-9568.2000.00164.x
10.1073/pnas.0511065103
10.1016/S0028-3908(99)00019-2
10.1056/NEJMoa013128
10.1001/jama.291.3.317
10.1016/S0014-2999(98)00112-5
10.1037/0735-7044.118.3.643
Hampson RE, 1998, Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance, J Neurosci, 18, 2740, 10.1523/JNEUROSCI.18-07-02740.1998
10.1111/j.1527-3458.2002.tb00228.x
10.1016/S0006-8993(03)02357-6
10.1016/j.neuropharm.2003.07.002
10.1371/journal.pbio.0030299
10.1097/00019442-200201000-00004
Lovestone S, 1994, Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells, Curr Biol, 4, 1077, 10.1016/S0960-9822(00)00246-3
10.1016/S0006-3223(98)00183-8
10.1073/pnas.0500466102
10.1038/nature01640
10.1073/pnas.1630428100
10.1523/JNEUROSCI.22-06-02035.2002
10.1006/nbdi.2001.0449
10.1002/ana.10680
10.1016/j.nbd.2004.12.004
10.1016/j.expneurol.2005.10.011
10.1021/jm050896o
10.1016/0306-4522(94)90311-5
Kennedy BP, 2003, Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease, J Neural Transm, 110, 789, 10.1007/s00702-003-0828-6
10.1002/jnr.20350
10.1111/j.0953-816X.2004.03377.x
10.1002/neu.10151
10.1016/j.cbi.2006.11.008
10.1111/j.1527-3458.2004.tb00010.x
10.1136/jnnp.72.3.310
10.1176/appi.ajp.160.11.2003
10.1016/j.tips.2004.12.010
10.1097/01.wad.0000213805.66811.31
10.1016/j.phrs.2003.12.027
10.1016/j.jalz.2006.02.001
10.1097/01.wad.0000213804.59187.2d
10.1016/S0924-977X(00)00067-5
10.1146/annurev.neuro.24.1.677
10.1146/annurev.neuro.24.1.1217
10.1042/CS20050163
10.1073/pnas.83.23.9231
10.1523/JNEUROSCI.17-19-07288.1997
10.1038/nm1239
10.1097/00004850-200109000-00002
10.1016/0306-4522(93)90429-J
10.1038/sj.bjp.0702545
10.1038/sj.bjp.0702910
10.1111/j.1527-3458.1997.tb00321.x
10.1097/00004424-200206000-00003
10.1007/s00702-003-0025-7
10.1007/s007020200092
10.1111/j.1468-1331.2006.01222.x
10.1073/pnas.96.19.10893
Tuszynski MH, 1996, Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration, Gene Ther, 3, 305
10.1097/00002093-200310000-00011
10.1038/nrn1495
10.1038/nrd938
10.1159/000054762
10.1038/nn842
10.1038/35050110
10.1186/1742-2094-1-24
Ferris SH, 2006, ADCS Prevention Instrument Project: overview and initial results, Alzheimer Dis Assoc Disord, 20, S109, 10.1097/01.wad.0000213870.40300.21
10.1212/01.WNL.0000042480.86872.03
10.1001/archneur.57.3.339
10.1212/01.wnl.0000167542.89697.0f
10.1001/archneur.64.1.108
10.1002/ana.20009
10.1001/jama.289.16.2094
10.1212/WNL.52.3.562
10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9
10.1002/ana.20558